54 research outputs found
Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Core binding factor acute myeloid leukemia (AML) comprises two
subtypes with distinct cytogenetic abnormalities of either
t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). Since longterm response to chemotherapy in these leukemias is relatively good,
allogeneic hematopoietic stem cell transplantation is considered in
patients who relapse and achieve second complete remission. To evaluate the outcomes of allogeneic transplantation in this indication, we
studied 631 patients reported to the European Society for Blood and
Marrow Transplantation Registry between the years 2000 and 2014.
Leukemia-free survival probabilities at two and five years were 59.1%
and 54.1%, while overall survival probabilities were 65% and 58.2%,
respectively. The incidence of relapse and risk of non-relapse mortality at
the same time points were 19.8% and 22.5% for relapse and 20.9% and
23.3% for non-relapse mortality, respectively. The most important
adverse factors influencing leukemia-free and overall survival were:
leukemia with t(8;21), presence of three or more additional chromosomal
abnormalities, and Karnofsky performance score <80. Relapse risk was
increased in t(8;21) leukemia and associated with additional cytogenetic
abnormalities as well as reduced intensity conditioning. Measurable
residual disease in molecular evaluation before transplantation was associated with increased risk of relapse and inferior leukemia-free survival
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
BACKGROUND: Acute graft-versus-host disease (GVHD) remains a major limitation of allogeneic stem-cell transplantation; not all patients have a response to standard glucocorticoid treatment. In a phase 2 trial, ruxolitinib, a selective Janus kinase (JAK1 and JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory acute GVHD. METHODS: We conducted a multicenter, randomized, open-label, phase 3 trial comparing the efficacy and safety of oral ruxolitinib (10 mg twice daily) with the investigator's choice of therapy from a list of nine commonly used options (control) in patients 12 years of age or older who had glucocorticoid-refractory acute GVHD after allogeneic stem-cell transplantation. The primary end point was overall response (complete response or partial response) at day 28. The key secondary end point was durable overall response at day 56. RESULTS: A total of 309 patients underwent randomization; 154 patients were assigned to the ruxolitinib group and 155 to the control group. Overall response at day 28 was higher in the ruxolitinib group than in the control group (62% [96 patients] vs. 39% [61]; odds ratio, 2.64; 95% confidence interval [CI], 1.65 to 4.22; P<0.001). Durable overall response at day 56 was higher in the ruxolitinib group than in the control group (40% [61 patients] vs. 22% [34]; odds ratio, 2.38; 95% CI, 1.43 to 3.94; P<0.001). The estimated cumulative incidence of loss of response at 6 months was 10% in the ruxolitinib group and 39% in the control group. The median failure-free survival was considerably longer with ruxolitinib than with control (5.0 months vs. 1.0 month; hazard ratio for relapse or progression of hematologic disease, non-relapse-related death, or addition of new systemic therapy for acute GVHD, 0.46; 95% CI, 0.35 to 0.60). The median overall survival was 11.1 months in the ruxolitinib group and 6.5 months in the control group (hazard ratio for death, 0.83; 95% CI, 0.60 to 1.15). The most common adverse events up to day 28 were thrombocytopenia (in 50 of 152 patients [33%] in the ruxolitinib group and 27 of 150 [18%] in the control group), anemia (in 46 [30%] and 42 [28%], respectively), and cytomegalovirus infection (in 39 [26%] and 31 [21%]). CONCLUSIONS: Ruxolitinib therapy led to significant improvements in efficacy outcomes, with a higher incidence of thrombocytopenia, the most frequent toxic effect, than that observed with control therapy
Fecal microbiota transplantation in the treatment of acute gastrointestinal graft-versus-host disease: A retrospective survey of the transplant complications working party of EBMT
Cryptocurrency Value Formation: An Empirical Analysis Leading to a Cost of Production Model for Valuing Bitcoin.
Successful bone marrow transplantation for treatment of chronic myeloid leukemia from a donor with mosaic klinefelter syndrome
Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant
- …